Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Innovation ETF (ARKK) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

ARK Innovation ETFTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

ARK Innovation ETF vs Inovio Pharmaceuticals Inc — how do they compare? ARK Innovation ETF trades at $81.5, while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: ARK Innovation ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

ARKKINO
52-Week High
$92.50$2.87
52-Week Low
$63.52$0.66
Market Cap
$78.55M
Sector
Health
Enterprise Value
$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Innovation ETF

ARK Innovation ETF (ARKK) trades at $81.37, up 1.13% with a bullish technical signal from moving averages. The fund faces mixed sentiment with Seeking Alpha highlighting concentration risks and underperformance versus S&P 500, while Cathie Wood continues aggressive buying in AI stocks like CoreWeave. Technical indicators show overbought conditions with RSI at 91 on the 6-day timeframe.

Outlook remains challenged by high fees (0.75%), concentrated bets on Tesla and SpaceX, and limited AI exposure. The fund's venture-style approach creates volatility, with 37.88% losses over five years. Near-term performance hinges on Tesla's 10% weighting and AI stock momentum amid decelerating revenue growth in portfolio companies.

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ARK Innovation ETF

The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.

Read more on ARKK

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO